The Phase III clinical trials on Bio-E-Gel revealed that three doses of Bio-E-Gel significantly decrease the number of hot flashes in menopausal women. The bio-identical estradiol gel also produced low estradiol blood levels, had a good safety profile, with minimal application site irritation, a side effect associated with transdermal patches.

Bio-E-Gel(TM) utilizes Antares Pharma's proprietary Advanced Transdermal Delivery gel system to deliver the hormone estradiol through the skin. Antares Pharma has licensed its estradiol gel in its patented ATD� system to BioSante for North America, but retains all rights to develop, market and license its own estradiol ATD� gel products in Europe, Japan and other important markets.

Read more about the clinical trial here.